Henagliflozein/Metformin Hydrochloride

脯氨酸恒格列净/盐酸二甲双胍

Report date: 2025/03/31 10:39:19
NME

Base Information

Drug NameHenagliflozein/Metformin Hydrochloride
Drug Alias NameHenagliflozein Proline/Metformin Hydrochloride脯氨酸恒格列净/盐酸二甲双胍恒格列净二甲双胍缓释瑞沁达HR-20033 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitorsProtein kinase AMP-activated non-catalytic subunit beta 1 activators
TargetsSodium/glucose cotransporter 2Protein kinase AMP-activated non-catalytic subunit beta 1
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryMainland China
Original Approved Date2023/12/29
Country/TerritoryMainland China
CombinationsYes Henagliflozin ProlineMetformin Hydrochloride
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShandong Shengdi Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShandong Shengdi Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A